BACKGROUND: Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable coronary artery disease. METHODS: In this multicentre, double-blind, randomised, placebo-controlled, outpatient trial, patients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospitals, clinics, or community centres in 33 countries. This paper reports on patients with coronary artery disease. Eligible patients with coronary artery disease had to have had a myocardial infarction in the past 20 years, multi-vessel coronary artery disease, history of stable or unstable angina, previous multi-vessel percutaneous coronary intervention, or previous multi-vessel coronary artery bypass graft surgery. After a 30-day run in period, patients were randomly assigned (1:1:1) to receive rivaroxaban (2·5 mg orally twice a day) plus aspirin (100 mg once a day), rivaroxaban alone (5 mg orally twice a day), or aspirin alone (100 mg orally once a day). Randomisation was computer generated. Each treatment group was double dummy, and the patients, investigators, and central study staff were masked to treatment allocation. The primary outcome of the COMPASS trial was the occurrence of myocardial infarction, stroke, or cardiovascular death. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants. FINDINGS: Between March 12, 2013, and May 10, 2016, 27 395 patients were enrolled to the COMPASS trial, of whom 24 824 patients had stable coronary artery disease from 558 centres. The combination of rivaroxaban plus aspirin reduced the primary outcome more than aspirin alone (347 [4%] of 8313 vs 460 [6%] of 8261; hazard ratio [HR] 0·74, 95% CI 0·65-0·86, p<0·0001). By comparison, treatment with rivaroxaban alone did not significantly improve the primary outcome when compared with treatment with aspirin alone (411 [5%] of 8250 vs 460 [6%] of 8261; HR 0·89, 95% CI 0·78-1·02, p=0·094). Combined rivaroxaban plus aspirin treatment resulted in more major bleeds than treatment with aspirin alone (263 [3%] of 8313 vs 158 [2%] of 8261; HR 1·66, 95% CI 1·37-2·03, p<0·0001), and similarly, more bleeds were seen in the rivaroxaban alone group than in the aspirin alone group (236 [3%] of 8250 vs 158 [2%] of 8261; HR 1·51, 95% CI 1·23-1·84, p<0·0001). The most common site of major bleeding was gastrointestinal, occurring in 130 [2%] patients who received combined rivaroxaban plus aspirin, in 84 [1%] patients who received rivaroxaban alone, and in 61 [1%] patients who received aspirin alone. Rivaroxaban plus aspirin reduced mortality when compared with aspirin alone (262 [3%] of 8313 vs 339 [4%] of 8261; HR 0·77, 95% CI 0·65-0·90, p=0·0012). INTERPRETATION: In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding. There was no significant increase in intracranial bleeding or other critical organ bleeding. There was also a significant net benefit in favour of rivaroxaban plus aspirin and deaths were reduced by 23%. Thus, addition of rivaroxaban to aspirin has the potential to substantially reduce morbidity and mortality from coronary artery disease worldwide. FUNDING: Bayer AG.

ANMCO Research Center Florence Italy

Bayer AG Parsippany NJ USA

Bayer AG Wuppertal Germany

Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School Boston MA USA

Charles University Prague Czech Republic

Collegium Medicum Jagiellonian University Krakow Poland; University of Glasgow Glasgow UK

Department of Medicine National University of Ireland Galway Ireland

Department of Medicine Semmelweis University Budapest Hungary

Department of Medicine Turku University Central Hospital and Turku University Turku Finland

Department of Medicine University of Edinburgh Edinburgh UK

Department of Medicine University of Philippines Manila Philippines

Department of Medicine University of Washington Medical Centre Seattle WA USA

FuWai Hospital CAMS Beijing China

Institut Universitaire de Cardiologie et Pneumologie de Québec Québec QC Canada

Institute of Cardiology Kiev Ukraine

Instituto Dante Pazzanese de Cardiologia and University Santo Amaro Saõ Paulo Brazil

Monash University Melbourne VIC Australia

Osaka International Cancer Institute Osaka Japan

Population Health Research Institute McMaster University and Hamilton Health Sciences Hamilton ON Canada

School of Rehabilitation Science McMaster University Hamilton ON Canada

Universidad de la Frontera Temuco Chile

Universidad Tecnológica Equinoccial Facultad de Ciencias de la Salud Eugenio Espejo Quito Ecuador

Universiti Teknologi Mara Selangor Malaysia

University of Aalborg Aalborg Denmark

Yonsei University College of Medicine Seoul Korea

Lancet. 2018 Jan 20;391(10117):181-182. doi: 10.1016/S0140-6736(17)32816-7. PubMed

Nat Rev Cardiol. 2018 Jan;15(1):3. doi: 10.1038/nrcardio.2017.192. PubMed

Lancet. 2018 Jan 20;391(10117):204. doi: 10.1016/S0140-6736(17)33365-2. PubMed

Citace poskytuje Crossref.org

Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01776424